Evidence map›Paper›PMID 40406148›Full record

ArticleFrontiers in immunology2025

Decoding multiple myeloma: single-cell insights into tumor heterogeneity, immune dynamics, and disease progression.

Zhenzhen Zhao, Zhijie Zhao, Zhiheng Lin, Lu Fan, Zhikai Xiahou, Yujiang Dong, Weiying Bao

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Integrative single-cell analysis revealsFrontiers in immunology · 2026
    Article
  6. Cross-modal fusion of cytomorphology andFrontiers in immunology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhenzhen Zhao *The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China.
Zhijie Zhao *Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Zhiheng Lin *Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Lu FanDepartment of Hematology, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhikai XiahouChina Institute of Sport and Health Science, Beijing Sport University, Beijing, China.
Yujiang DongThe Second Affiliated Hospital of Shandong University of Chinese Medicine, Department of Cardiovascular Disease, Jinan, China.
Weiying BaoDepartment of Hematology, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multiple myeloma (MM) is a biologically heterogeneous malignancy of clonal plasma cells, often progressing from MGUS or smoldering MM. It causes anemia, bone lesions, and immune dysfunction due to abnormal plasma cell expansion in the bone marrow. Neuroinflammatory and neurotrophic factors may influence MM progression by affecting immune cells and the bone marrow niche. Growing evidence points to a role for neuroimmune regulation in tumor immunity. Despite therapeutic progress, disease heterogeneity and resistance highlight the need for new strategies targeting the tumor microenvironment and neuroimmune axis. Methods: This investigation exploited single-cell RNA sequencing (scRNA-seq) to analyze MM and high-risk smoldering multiple myeloma (SMMh) samples, identifying 11 distinct cell types. We examined their transcriptional signatures, stemness, proliferative properties, and metabolic pathways, with particular attention to neuroimmune interactions in the tumor microenvironment. Using trajectory inference tools such as CytoTRACE, Monocle2, and Slingshot, we traced the differentiation paths of MM cell subpopulations and identified key signaling pathways that may influence immune responses and tumor progression. Results: The analysis identified four distinct subpopulations of myeloma cells, with the C0 Conclusion: This single-cell analysis provided new insights into the cellular diversity and differentiation trajectories in MM, offering a deeper understanding of the complex neuroimmune interactions that drive tumor progression and resistance. By incorporating the role of neuroinflammation and immune modulation, our study suggested novel therapeutic strategies targeting the neuroimmune axis in oncology, ultimately contributing to the development of more effective, personalized treatment approaches for MM.

Indexed as

Multiple MyelomaSingle-Cell AnalysisDisease ProgressionHumansRNA-SeqTumor MicroenvironmentAPPIGLC3MIFmultiple myelomaneuroimmunityNR3C1ScRNA-seq

Identifiers

PMID40406148
PMCPMC12095158

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.